23 research outputs found
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells
Get PDFGraft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients
No full textChemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer?
No full textISO-CC-005: A phase I/II study of Modufolin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin +/- bevacizumab in patients with metastasizing colorectal cancer.
No full textThe Chief Executive
Get PDFBACKGROUND: We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with or without cetuximab. PATIENTS AND METHODS: A total of 566 patients in the NORDIC VII Study were randomized 1â¶1â¶1 to arm A (Nordic FLOX), arm B (Nordic FLOX + cetuximab), or arm C (Nordic FLOX + cetuximab for 16 weeks followed by cetuximab alone as maintenance therapy). Pretreatment plasma samples were available from 510 patients. Plasma YKL-40 was determined by ELISA and dichotomized according to the age-corrected 95% YKL-40 level in 3130 healthy subjects. RESULTS: Pretreatment plasma YKL-40 was elevated in 204 patients (40%), and median YKL-40 was higher in patients with mCRC than in healthy subjects (age adjusted, P<0.001). Patients with elevated YKL-40 had shorter PFS than patients with normal YKL-40 (7.5 vs. 8.2 months; hazard ratio (HR) â=â1.27 95% confidence interval (CI) 1.05â1.53 Pâ=â0.013) and shorter OS (16.8 vs. 23.9 months; HRâ=â1.33, 1.04â1.69, Pâ=â0.024). Multivariate Cox analysis demonstrated that elevated pretreatment YKL-40 was an independent biomarker of short OS (HRâ=â1.12, 1.01â1.25, Pâ=â0.033). The ratio of the updated plasma YKL-40 (i.e. level after 1, 2, 8 weeks of treatment, and at end of treatment compared to the baseline level) was associated with OS (HRâ=â1.27, 1.06â1.52, Pâ=â0.011). CONCLUSIONS: Plasma YKL-40 is an independent prognostic biomarker in patients with mCRC treated with first-line oxaliplatin-based therapy alone or combined with cetuximab
Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab
No full textTIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in <i>KRAS</i>-mutated colorectal cancer cells:A potential novel approach to the treatment of metastatic colorectal cancer
No full textTIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in <i>KRAS</i>-mutated colorectal cancer cells:A potential novel approach to the treatment of metastatic colorectal cancer
Get PDFConsort diagram indicating sample sizes at each stage during the study.
No full text<p>Consort diagram indicating sample sizes at each stage during the study.</p
Demographic and Baseline Clinical Characteristics of the 510 patients with mCRC included in the Nordic VII Study with pretreatment plasma YKL-40.
No full text<p>Demographic and Baseline Clinical Characteristics of the 510 patients with mCRC included in the Nordic VII Study with pretreatment plasma YKL-40.</p
